title: Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery.
abstract: OBJECTIVE
  To determine the minimum effective dosage, most effective route of administration and long-term effects of mitomycin C for prevention of recurrence after pterygium surgery.
  
  
  METHODS
  In a prospective, masked study, 227 patients undergoing surgery for primary pterygia were assigned randomly to five groups: group 1 received a single intraoperative application of 0.2 mg/ml mitomycin C for 3 minutes; group 2 received a single intraoperative application of 0.4 mg/ml mitomycin C for 3 minutes; group 3 received mitomycin C eye drops 0.2 mg/ml three times daily for 7 days; group 4 received mitomycin C eye drops 0.4 mg/ml three times daily for 14 days; group 5 acted as a control (surgery alone).
  
  
  RESULTS
  After a mean follow-up time of 28 months, recurrence rates of 6.66%, 4.08%, 4.26%, 4.44%, and 29.27%, respectively, were observed. Statistical analysis showed significant differences between groups receiving mitomycin C and the control (P < or = 0.001). There was no statistical difference among treated groups (P > or = 0.0681). No complications of therapy were observed.
  
  
  CONCLUSIONS
  These results support the efficacy and relative safety of a single, low-concentration, intraoperative application of mitomycin C in pterygium surgery together with the use of a conjunctival flap, avoiding excessive cauterization of the sclera and leaving bare sclera.
authors.affiliation: Department of Ophthalmology, Unicamp Medical School, Campinas-SP, Brazil.
authors.forename: J A
authors.initials: JA
authors.lastname: Cardillo
authors.forename: M R
authors.initials: MR
authors.lastname: Alves
authors.forename: L E
authors.initials: LE
authors.lastname: Ambrosio
authors.forename: M B
authors.initials: MB
authors.lastname: Poterio
authors.forename: N K
authors.initials: NK
authors.lastname: Jose
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D003228:Conjunctiva / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009883:Ophthalmic Solutions; D011182:Postoperative Care; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000517:prevention & control / Q000601:surgery*; D012008:Recurrence; D012449:Safety; D013524:Surgical Flaps; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin